Prominent medical center is first in the United States to expand breast
health offerings with iCAD’s PowerLook Tomo Detection solution and Xoft System


NASHUA, N.H., and Macon, GA, (October 30, 2018) – iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today announced that its complete suite of leading-edge
breast health innovations including PowerLook® Tomo Detection, a radiology workflow solution
built on artificial
and the Xoft®
Axxent® Electronic Brachytherapy (eBx®) System®
the treatment of early-stage breast cancer using intraoperative radiation
therapy (IORT), are now available at The Medical Center, NavicentHealth, the second largest hospital in Georgia. Navicent
Health, based in Macon, Ga., is now the first health system in the country to offer
iCAD’s most advanced solutions for both the detection and treatment of breast


The hospital is also the first in the state to offer IORT
with the Xoft System. The comprehensive technologies are available at Navicent
Health’s Peyton Anderson Cancer Center and mark an important advancement for
the more than 8,000 women who will
be diagnosed with breast cancer this year in Georgia. The new offerings also
coincide with the hospital’s “Paint the Town Pink” community campaign for National
Breast Cancer Awareness Month in October.


adoption of iCAD’s premier products for the detection and treatment of breast
cancer underscores our commitment to elevating health and well-being through compassionate,
personalized care,” said Dr. Ninfa M. Saunders, FACHE, President
and CEO, Navicent Health. “With the addition of PowerLook Tomo Detection and
Xoft IORT, our providers are armed with proven technological advancements that offer
our patients valuable, life-changing benefits.”


“iCAD is
committed to delivering revolutionary technology that supports healthcare
professionals in providing quality care to patients worldwide,” said Ken Ferry,
CEO, iCAD. “We are pleased to partner with
Navicent Health, making it
possible for clinicians at this nationally recognized center to improve their
breast cancer detection and treatment programs that will have a lasting impact
in their community.”


Artificial Intelligence Technology

Tomo Detection is an innovative cancer detection solution for digital breast 3D
tomosynthesis (DBT) that incorporates artificial intelligence to optimize workflow
efficiencies and support decision making.
technology utilizes a trained, deep learning algorithm that automatically
analyzes each tomosynthesis slice,
providing radiologists with a single, highly-sensitive,
enhanced image that is used to easily navigate these expansive datasets. PowerLook
Tomo Detection is
clinically proven to optimize radiologists’ image reading and interpretation
by reducing read-time by an average of 29.2 percent. The solution is the first
and only U.S.
Food and Drug Administration (FDA) approved
concurrent-read cancer detection solution for DBT, is CE marked, and is
currently available in the U.S., Europe and Canada. iCAD’s PowerLook breast
health solutions support more than 3,500 healthcare facilities worldwide.


Radiation Therapy Treatment

Xoft IORT is a radiation treatment that uses a miniaturized X-ray
source to deliver a full course of targeted radiation inside the body, directly
within the tumor cavity at the time of breast conserving surgery (lumpectomy).
IORT allows radiation oncologists and breast cancer surgeons to work together
to offer appropriately selected patients an option to avoid the need for six to
seven weeks of post-operative external beam radiation therapy (EBRT). A
recent study found IORT to be the preferred method of treatment as
compared to EBRT, due to significant cost savings, reduced radiation exposure
and improved quality of life.
The Xoft System is cleared by the FDA, CE
marked and licensed in a growing number of countries for the treatment of
cancer anywhere in the body, including early-stage breast cancer, non-melanoma
skin cancer and gynecological cancers. It has been used to successfully treat
more than 15,000 patients worldwide.


About iCAD, Inc.


Headquartered in Nashua, NH, iCAD is a global
medical technology leader providing innovative cancer detection and therapy
solutions. For more information, visit


About Navicent Health


Navicent Health was incorporated on November 17, 1994, as
a nonprofit corporation whose primary purpose is to coordinate The Medical
Center, Navicent Health and other affiliated entities in their mission of
providing a comprehensive continuum of high quality, reasonably priced
healthcare services to the region. Navicent Health has 970 beds for medical,
surgical, rehabilitation and hospice purposes. The health system includes The
Medical Center, Navicent Health, a nationally recognized tertiary teaching hospital;
Beverly Knight Olson Children’s Hospital, Navicent Health, the region’s only
dedicated pediatric hospital; Navicent Health Baldwin and Medical Center of
Peach County, Navicent Health, both rural hospitals; Rehabilitation Hospital,
Navicent Health, the region’s oldest and most experienced rehabilitation
provider; Pine Pointe, Navicent Health, which provides palliative and hospice
care in homes and in its facility; Carlyle Place, Navicent Health, the area’s
first continuing care retirement community; Navicent Health Foundation, the
philanthropic arm of Navicent Health; as well as diagnostic and home care
services. For more information, please visit


“Safe Harbor” Statement under the Private
Securities Litigation Reform Act of 1995


Certain statements contained in this News Release
constitute “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements
involve a number of known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of the Company
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors include,
but are not limited to the Company’s ability to defend itself in litigation
matters, to achieve business and strategic objectives, the risks of uncertainty
of patent protection, the impact of supply and manufacturing constraints or
difficulties, uncertainty of future sales levels, protection of patents and
other proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, litigation and/or government
regulation, changes in Medicare or other reimbursement policies, risks relating
to our existing and future debt obligations, competitive factors, the effects
of a decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”,
“consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”,
“seek”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, including the 10-K for the year ended December 31, 2017,
available on the Investors section of our website at and on the SEC’s
website at




Media Inquiries:

ARPR, on behalf of iCAD, Inc.

Paul Barren, (855) 300-8209


Navicent Health:

Megan Allen, (478) 550-4380


Investor Relations:

LifeSci Advisors

Jeremy Feffer, (212) 915-2568